We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
S and W Seed Company | NASDAQ:SANW | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00975 | 2.60% | 0.38445 | 0.38 | 0.3888 | 0.409899 | 0.38 | 0.38 | 24,659 | 18:41:28 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in Its charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange on Which Registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 15, 2023, upon recommendation of the Nominating and Governance Committee of the Board of Directors (the "Board") of S&W Seed Company (the "Company"), the Board approved an increase in the size of the Board to six members and appointed Jeffrey Rona to fill the vacancy created by such increase, to serve as a director of the Company until the 2024 Annual Meeting of Stockholders, and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Rona was appointed as a member and chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.
The Company will enter into its standard form of indemnification agreement for its directors with Mr. Rona. In addition, pursuant to the Company's non-employee director compensation policy, Mr. Rona will receive pro-rated cash and equity compensation measured as of the effective date of his appointment to the Board.
Mr. Rona has more than 30 years of experience as a Chief Business Officer, Chief Financial Officer, and investment banker. He is currently the Chief Business and Financial Officer of Ovid Therapeutics, a Nasdaq listed biopharmaceutical company. Prior to joining Ovid Therapeutics, he was the Western Region Managing Director for Danforth Advisors, a life science financial strategy consultancy. Prior to that, Mr. Rona held the titles of Chief Business Officer at GlobeImmune, Chief Financial Officer at AlgoRx Pharmaceuticals, and Director, Investment Banking at UBS. Over the span of his career, he has completed more than 50 transactions totaling $3.0 billion in deal value. Mr. Rona received his Bachelor of Science degree in accounting from Case Western Reserve University.
There is no arrangement or understanding between Mr. Rona and any other person pursuant to which Mr. Rona was appointed as a director. There are no transactions between the Company and Mr. Rona that would require disclosure under Item 404(a) of Regulation S-K.
On June 26, 2023, the Company disclosed on a Form 8-K that it was not in compliance with the audit committee requirements of Nasdaq Listing Rule 5605(c)(2)(A) as a result of the resignation of a director. With the appointment of Mr. Rona, the Company now complies with this rule.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
S&W SEED COMPANY |
|
|
|
|
|
|
|
|
By: |
/s/ Vanessa Baughman |
|
|
Vanessa Baughman |
|
|
Chief Financial Officer |
Date: December 19, 2023
Document and Entity Information |
Dec. 15, 2023 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | S&W SEED CO |
Security Exchange Name | NASDAQ |
Amendment Flag | false |
Entity Central Index Key | 0001477246 |
Document Type | 8-K |
Document Period End Date | Dec. 15, 2023 |
Entity Incorporation, State or Country Code | NV |
Entity File Number | 001-34719 |
Entity Tax Identification Number | 27-1275784 |
Entity Address, Address Line One | 2101 Ken Pratt Blvd |
Entity Address, Address Line Two | Suite 201 |
Entity Address, City or Town | Longmont |
Entity Address, State or Province | CO |
Entity Address, Postal Zip Code | 80501 |
City Area Code | (720) |
Local Phone Number | 506-9191 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | SANW |
Entity Emerging Growth Company | false |
1 Year S and W Seed Chart |
1 Month S and W Seed Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions